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In this work, the authors presented the techniques and the preliminary results at 6 months of a randomized controlled trial
(NCT02117999) comparing a novel transepithelial corneal cross-linking protocol using iontophoresis with the Dresden protocol
for the treatment of progressive keratoconus. At 6 months, there was a significant average improvement with an average flattening
of the maximum simulated keratometry reading of 0.72 ± 1.20D (𝑃 = 0.01); in addition, corrected distance visual acuity improved
significantly (𝑃 = 0.08) and spherical equivalent refraction was significantly less myopic (𝑃 = 0.02) 6 months after transepithelial
corneal cross-linking with iontophoresis.The novel protocol using iontophoresis showed comparable results with standard corneal
cross-linking to halt progression of keratoconus during 6-month follow-up. Investigation of the long-term RCT outcomes are
ongoing to verify the efficacy of this transepithelial corneal cross-linking protocol and to determine if it may be comparable with
standard corneal cross-linking in the management of progressive keratoconus.
1. Introduction
Corneal cross-linking is an established procedure aimed
at slowing down or halting keratoconus progression [1].
The efficacy of the conventional riboflavin/UV-A irradiation
procedure was primarily demonstrated by laboratory studies
suggesting that it increases the biomechanical strength of
the treated cornea. In addition, several clinical studies have
evidenced how the treatment is effective in slowing down
or halting the progression of keratoconus up to 10 years of
follow-up [2–9].
The conventional corneal cross-linking procedure
includes the removal of corneal epithelium to permit
adequate penetration of riboflavin in the stroma. Epithelial
removal, however, is responsible for most of the major cross-
linking related complications, which include postoperative
pain, vision impairment, and risk of infection. Major efforts
have been dedicated to overcoming the epithelial barrier
to riboflavin penetration and reducing treatment time,
with the aim of maintaining efficacy and improving safety
of the treatment [10]. On the other hand, there are still
controversies on how riboflavin may penetrate in the stroma
through an intact epithelium or how the epithelium may
limit UV-A irradiation of the stroma soaked by riboflavin.
It has been widely shown that dextran-enriched solutions
greatly limit the penetration of riboflavin in the stroma
through the intact epithelium [10, 11]. Recently, Shalchi et al.
[12] have revised a series of peer-reviewed papers comparing
the results of standard cross-linking (total of 45 papers) and
transepithelial cross-linking (total of 5 papers) in the man-
agement of progressive keratoconus. Although transepithelial
corneal cross-linking has been shown to be safe without
any related epithelial wound healing complication, 75% of
the cases have shown a continued keratoconus progression
one year after treatment, whereas the majority of studies
on standard cross-linking (≥90%) have shown reduction
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in maximum simulated keratometry in the same period.
The only study that has shown comparable results between
transepithelial and standard corneal cross-linking did not use
dextran-enriched riboflavin solution for the transepithelial
treatment [12].
Overall, the limited number of published outcomes from
randomized controlled trials (RCTs) makes it challenging
to draw clear conclusions on the efficacy of the many
techniques used for transepithelial corneal cross-linking
[13–20]. Robustly designed controlled trials are required
to provide accurate results between techniques. Currently,
five RCTs (NCT02117999, NCT02456961, NCT02349165,
NCT01181219, and NCT01868620) are aiming to compare the
results of transepithelial corneal cross-linking with the stan-
dard procedure for stabilization of progressive keratoconus;
three of these trials (NCT02117999, NCT02456961, and
NCT01868620) are using dextran-free riboflavin solutions to
moisten the corneal stroma through the intact epithelium
using iontophoresis.
Iontophoresis is a noninvasive technique used to deliver a
charged substance transcorneally by repulsive electromotive
force using a small electrical charge applied to an ion-
tophoretic chamber. In ex vivo studies, we have assessed the
diffusion of riboflavin in dextran-free 0.1% hypotonic solu-
tion enriched with ethylenediaminetetraacetic acid (EDTA)
and trometamol in the corneal stroma of eye bank donor
eyes and the effect of rapid UV-A irradiation of the cornea
(i.e., 10mW/cm2 for 9 minutes) after transepithelial soaking
using iontophoresis. Experimental work has demonstrated
that though the stromal concentration of riboflavin after
iontophoresis was lower than conventional soaking, the stiff-
ening effect on the anterior cornea was almost comparable
to that of standard cross-linking [21, 22]. Other laboratory
studies have shown that iontophoresis is effective to deliver
an adequate amount of riboflavin in the stroma through the
intact epithelium, as previously discussed [21, 22].
The present RCT with identifier code NCT02117999 was
designed to compare the treatment efficacy for progressive
keratoconus by transepithelial corneal cross-linking using
iontophoresis with the standard corneal cross-linking proce-
dure at 12months. In this paper, we present the technique and
anticipate the outcomes from the complete cohort of 34 eyes
after 6 months of follow-up.
2. Patients and Methods
2.1. Study Design. This is an ongoing prospective, unmasked,
randomized controlled trial (RCT) conducted at the clinical
trials center of the IRCCS FondazioneG.B. Bietti, Rome, Italy.
The aim of the study is to assess the efficacy and safety of
transepithelial corneal cross-linking using iontophoresis (T-
ionto CL or study group) in the treatment of progressive
keratoconus in comparison with standard corneal cross-
linking (standardCL or control group).Theprimary outcome
measure of the study is the maximum simulated keratometry
value (𝐾max) at 12 months. Approval was obtained from
the IFO-IRCCS Ethical Committee (Rome, Italy), and the
conduct of the study adhered to the tenets of the Declaration
of Helsinki. The trial is registered with the US National Insti-
tutes of Health registry with identifier code NCT02117999
(https://clinicaltrials.gov/ct2/show/NCT02117999). After full
explanation of the protocol, written informed consent was
obtained from all participants before enrolment in the study.
The recruitment started on January 31, 2014, and closed on
May 30, 2015.
2.2. Participants. Patients with a confirmed diagnosis of
progressive keratoconus were invited to participate in this
study. Keratoconus was deemed to be progressive if there
was an increase of at least 1 diopter (D) in 𝐾max derived
by computerized Placido disk corneal topography over the
preceding 12 months. Exclusion criteria included aminimum
corneal thickness of less than 400𝜇m,𝐾max steeper than 61D,
any corneal scarring, previous refractive or other corneal or
ocular surgeries, and other ocular disorders (e.g., cataract,
glaucoma, andherpetic keratitis). Patientswhowere pregnant
or breastfeeding at the time of enrolment also were excluded.
Only patients aged between 18 and 46 years were included in
the study.
Eligible patients were randomized after enrolment, with
allocation ratio of 2 : 1, into either the study or control group
using a computer-generated randomization plan with block
randomization in groups of four. Two different blocks were
created, which included eyes with𝐾max steeper or flatter than
54D in order to randomize patients with similar baseline
𝐾max values in the study and control groups. If both eyes
of a patient qualified for participation in the study, each eye
was randomized independently. Second eyes were treated no
earlier than 2 months after the first eyes.
2.3. Assessments. Contact lens wearers were instructed to
discontinue their use for a minimum of 3 weeks before the
preoperative eye examination. In addition, we asked all those
patients to discontinue the use of contact lens during follow-
up in order to avoid bias during the study.
At baseline and postoperative visits at 3 and 7 days
and 1, 3, and 6 months, all patients underwent slit-lamp
examination of the anterior segment of the eye; the haze
in the anterior stroma was graded on a scale (grade 0–4)
used after photorefractive keratectomy [23]; ocular surface
inflammation was graded on signs of bulbar conjunctival
hyperemia (grade 0–3) and upper tarsal conjunctival papillae
(grade 0–3) according to Akpek et al. [24]. In addition, the
following assessmentswere recorded: best spectacle corrected
visual acuity (BSCVA, logMAR units) obtained using Early
Treatment Diabetic Retinopathy Study chart at 4 meters,
contrast sensitivity function (CSF, log units) evaluated using
Pelli-Robson chart, manifest refraction (expressed as spheri-
cal equivalent, diopters, D), 𝐾max (D) and corneal thickness
(micrometers, 𝜇m) using combined Placido disk corneal
topography and anterior segment optical coherence tomog-
raphy (Visante, Carl Zeiss Meditec Inc., Dublin, CA, USA),
and endothelial cell density (ECD, cells/mm2) measured by
no-contact specular microscopy (Perseus, CSO, Italy). All
data were acquired and analyzed in an unmasked manner. At
each time point, patients received a questionnaire to evaluate
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Figure 1: (A) Slit-lamp photograph of the cornea 1 minute after the applanation with the Biopore membrane. (B) The corneal epithelium
showed moderate punctate staining with fluorescein dye (molecular weight: 376Da). (C) Homogeneous immunofluorescent staining for
MUC4mucin (false color red) was found on Bioporemembranes where the cornea was applanated. (D) A small number of scattered epithelial
cells (false color blue) were observed on the membranes. In (C) and (D), scale bars are 100 𝜇m. (E) Iontophoresis was performed with the
current intensity set at 1.0mA for 5 minutes using a commercial device. (F) After iontophoresis, the cornea was irradiated using 10mW/cm2
UV-A device for 9 minutes. The arrow indicates the mark of the suction tube on the corneal epithelium. Strong fluorescence was emitted by
stromal riboflavin inside the area of iontophoresis delivery.
symptoms, such as itchiness, tearing, photophobia, and pain
(grade 0–3), after treatment.
To exclude infection, document epithelial healing, and
provide general postoperative care, all patients were assessed
also on day 1 after treatment in addition to the described
follow-up schedule.
To improve the reliability of topography measurements,
a minimum of 3 acquisitions were performed for each eye
at each time interval. If the value varied by more than 10%
between the scans, then a further scan was obtained.The best
scan was then selected for analysis.
2.4. Techniques and Treatments. For each patient, corneal
cross-linking was performed within 4 weeks of the base-
line examination. All treatments were performed under
topical anaesthesia; anaesthetic eye drops (oxybuprocaine
hydrochloride 0.4%, Novesina, Novartis Farma SpA, Italy)
were instilled 3 times over a 10-minute period before each
treatment. Transepithelial corneal cross-linking using ion-
tophoresis was performed as follows (Figure 1):
(1) After a lid speculum was inserted, central corneal
thickness was measured by handheld ultrasound
4 Journal of Ophthalmology
pachymeter (Pachmate, DGH, Exton, USA); there-
after, sterile Biopore membrane attached to a plastic
cylinder (Millicell, cod. PICM01250, Merck SpA,
Italy) was pressed against the central cornea with
sufficient pressure to applanate the central cornea for
3 seconds and remove the precorneal mucin layer.
(2) Corneal soaking with ETDA and trometamol
enriched riboflavin-5-phosphate 0.1% hypotonic
solution (Ricrolin+, Sooft Italia SpA, Italy) was
performed using a commercial iontophoresis device
(Iontophor CXL, Sooft Italia SpA, Italy). The passive
electrode was applied to the forefront of the eye to
be treated. The active electrode, a bath tube made
of plastic, was applied to the corneal surface. After
suctioning of the tube to the corneal epithelium,
it was filled with riboflavin solution. The current
intensity was set at 1.0mA for 5 minutes. After
iontophoresis, the corneal surface was gently washed
with chilled 0.9% sodium chloride solution.
(3) Immediately after iontophoresis, the central corneal
thickness was again measured by handheld ultra-
sound pachymeter.
(4) Corneal UV-A irradiation was then applied using
10mW/cm2 device (370 ± 8 nm; Vega 10mW, CSO,
Italy) at 56mm distance for 9 minutes. One drop of
chilled 0.9% sodium chloride solution was applied
over the corneal epithelium every 3 minutes during
irradiation.
The control group received conventional corneal cross-
linking according to the “Dresden protocol” [3, 4]. The
central 10mmcorneal epitheliumwas removed usingAmoils’
brush (Innovative Excimer Solutions Inc., Toronto, ON);
central stromal thickness was then measured by handheld
ultrasound pachymeter. A solution containing 20% dextran-
enriched 0.1% riboflavin (Ricrolin, Sooft Italia SpA, Italy)
was instilled every 3 minutes for 30 minutes before UV-
A irradiation. After corneal soaking, the stromal surface of
each tissue was gently washed using chilled 0.9% sodium
chloride solution; thereafter, the central stromal thickness
was measured by handheld ultrasound pachymeter. The
corneal stroma was then irradiated with a UV-A device (Vega
3mW, 370 ± 8 nm) with an irradiance of 3mW/cm2 for
30 minutes. The UV-Adelivery system was located 56mm
from the cornea. Diluted riboflavin (0.025%) drops were
instilled over the stromal surface every 3minutes during UV-
A irradiation.
The UV-A devices were calibrated with a power meter
before corneal irradiation and an irradiation area of 9.00mm
diameter was used in all cases.
At the end of treatments, 2 drops of ofloxacin 0.3%
(Monofloxofta, Sooft Italia SpA, Italy) were applied in all
cases. A bandage contact lens was applied only to patients
treated by conventional corneal cross-linking; it remained in
place until epithelial closure was confirmed. After surgery, all
patients continued taking ofloxacin 0.3% 5 times daily for 6
days, sodium hyaluronate 0.10% (Ribolisin, Sooft Italia SpA,
Italy) 6 times daily for 3months, and fluorometholone acetate
0.1% (Fluaton, Bausch & Lomb, Rochester, NY) 2 times daily
from day 7 to day 21.
2.5. Immunofluorescence Microscopy Imaging. Immediately
after the applanation, the Biopore membranes were fixed in
4% paraformaldehyde and shipped to the laboratory. Each
membrane was gently removed from the plastic cylinder and
placed into the wells of a multiwell plate. The samples were
blocked in 1x phosphate buffered saline containing 1% bovine
serum albumin (BSA; Sigma-Aldrich, Saint Louis, MO) and
then incubated with antibody against mucin-4 (MUC4, goat
polyclonal, 1 : 100; Santa Cruz Biotechnology, Santa Cruz,
CA) for 2 hours and with rhodamine-conjugated secondary
antibodies (anti-goat produced in donkey, 1 : 200; Sigma-
Aldrich, Saint Louis, MO) for 1 hour at room temperature. In
addition, the cell nuclei were stained with far-red fluorescent
DNA dye (DRAQ5, 1 : 2000; Cell Signaling Technology,
Boston, MA) for 10 minutes at room temperature. Spec-
imens were then mounted in Dako Glycergel mounting
medium (Dako, Glostrup, Denmark) for immunofluores-
cence microscopy imaging. Images were acquired using a
Nikon A1Rsi+ confocal laser scanning microscope equipped
with NIS-Elements Advanced Research software (Nikon
Instruments Inc., Melville, NY).
2.6. Statistical Analysis. Statistical analysis was performed
using SPSS (version 17, IBMCorp., NY). All data are reported
as the mean ± standard deviation. Normal data distribution
was tested by using the one-sample Kolmogorov-Smirnov
test. Sample size calculation was performed to detect a
difference of 0.95D between the mean 𝐾max changes for
the T-ionto CL and standard CL groups at 12 months, at a
significance level of 5% and power of > 80%, assuming a
standard deviation of 1.20D.The sample size of the study was
34 cases (allocation ratio of 2 : 1).
In this work, the difference from baseline for each param-
eter was calculated at each time point (3 days, 7 days, and 1, 3,
and 6months) for each eye.Thedifferenceswithin each group
were compared using paired Student’s 𝑡-test. These changes
were also compared between the study and control group
using unpaired Student’s 𝑡-test.
3. Results
Thirty-four eyes of 25 patients were randomized to T-ionto
CL (20 patients, 22 eyes) and standardCL (10 patients, 12 eyes)
treatments. The demographic data showed a strong skew
towardmale patients (20; 80%); themean age was 31.05±6.64
years and 29.40 ± 5.60 years in the study and control group
(𝑃 = 0.55), respectively. Eleven right eyes (50%) and eleven
left eyes (50%) were treated by T-ionto CL; seven right eyes
(60%) and five left eyes (40%) were treated by standard CL
(Table 1).
Nine patients were treated in both eyes: two patients
underwent T-ionto CL in both eyes (A100 and A500; A1600
and A2000); two patients underwent standard CL in both
eyes (B200 and B500; B300 and B400); and five patients
received T-ionto CL in one eye and standard CL in the fellow
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Table 1: Baseline demographics and clinical characteristics of eyes
in the study (T-ionto CL) and control (standard CL) groups (M ±
SD).
T-ionto CL Standard CL 𝑃 value
Age (years) 31.0 ± 6.6 29.4 ± 5.6 𝑃 = 0.55
Male/female gender (%) 18/3 (86%) 8/4 (67%)
𝐾max (D) 54.74 ± 4.01 54.76 ± 4.30 𝑃 = 0.87
BSCVA (logMAR) 0.12 ± 0.20 0.06 ± 0.10 𝑃 = 0.29
Central corneal thickness
point on AS-OCT (𝜇m) 484 ± 37 494 ± 34 𝑃 = 0.44
Spherical equivalent
refraction (D) −2.64 ± 2.41 −1.75 ± 2.12 𝑃 = 0.29
Endothelial cell density
(cells/mm2) 2635 ± 387 2625 ± 281 𝑃 = 0.93
𝐾max: maximumsimulated keratometry (D: diopters); BSCVA: best spectacle
corrected visual acuity (logMAR).
eye (A900 and B1100; A1300 and B1200; A1400 and B600;
A1500 and B700; A1800 and B900). All patients completed
the 6-month follow-up.
3.1. Technique. Immediately after corneal applanation with a
Biopore membrane, the corneal epithelium was moderately
stained with fluorescein dye (Figures 1(A) and 1(B)). The
Biopore membranes, which were applanated to the cornea,
showed confluent staining forMUC4mucin and the presence
of scattered epithelial cells in all cases (Figures 1(C) and 1(D)).
In the study group, two eyes (10%) had perilimbal
haemorrhage after removing the iontophoresis tube.This was
likely related to peripheral corneal suctioning of the tube.
One eye had a small central epithelial defect (<2mm) at the
end of the procedure. This was the first case in the series
(A100). A bandage contact lens was applied for 24 hours and
then removed once the epithelium was intact. In controls,
epithelial closurewas completed and the bandage contact lens
was removed at day 3 in all eyes.
In the study group, central corneal thickness ranged
between 491 ± 35 𝜇m and 492 ± 40 𝜇m (0.2% average
change) before and after iontophoresis, respectively. In the
control group, central stromal thickness decreased from 464±
34 𝜇m to 332 ± 27 𝜇m (28% average change) from before to
after soaking with 20% dextran-enriched riboflavin solution.
After UV-A irradiation of the cornea, the stromal thickness
returned back toward baseline values (445 ± 16 𝜇m).
3.2. Symptoms. At day 1, controls complained ofmore tearing
than those with eyes treated by T-ionto CL (𝑃 = 0.04);
no significant differences for other symptoms were found
between groups at day 1 postoperatively. At day 3, tearing
was again greater in patients treated by standard CL than
in those treated by T-ionto CL (𝑃 = 0.006); photophobia
was also greater in patients treated by standard CL than in
those treated by T-ionto CL (𝑃 = 0.001). No differences in
pain score were found between groups at day 1 (1.9 ± 1.0
and 2.1 ± 0.9 in T-ionto CL and standard CL groups, resp.,
𝑃 = 0.71) and day 3 (0.6 ± 0.5 and 0.5 ± 0.7, resp., 𝑃 =
0.65) postoperatively. After 1 week, there was no significant
symptom complained of by any patient and no difference was
found between groups.
3.3. Objective Evaluation. At day 1, bulbar conjunctival
hyperaemia was greater after standard CL than after T-ionto
CL, though without reaching statistical significance (𝑃 =
0.08); however, it was significantly greater 3 days (𝑃 < 0.001)
and 1week (𝑃 = 0.03) after standardCL than afterT-iontoCL.
Thereafter, no difference was found between groups. Upper
tarsal conjunctival papillae were greater at days 1 (𝑃 = 0.004)
and 3 (𝑃 < 0.001) after standard CL than after T-ionto CL.
No difference was found between groups afterwards.
Two eyes (10%) and six eyes (50%) showed stromal edema
in the T-ionto CL and control groups, respectively, both at
3 and at 7 days postoperatively. Thereafter, no edema was
evidenced in the study group. Corneal edema, which was
mostly confined to the posterior stroma, was still found in
4 eyes (33%) and 1 eye (8%) at 3 and 6 months after standard
CL, respectively.
At 3 months, two eyes (10%) in the T-ionto CL showed
faint corneal haze (grade: ≤0.50); at 6 months, all the eyes in
the T-ionto CL group had clear cornea. In the control group,
at 3 months, haze graded 0.50 in four eyes (33%) and 1.00 in
two eyes (17%); at 6 months, haze graded 0.5 and 1.00 in five
eyes (42%) and one eye (8%), respectively.
Representative pictures of study and control eyes over 6
months of follow-up are shown in Figure 2.
3.4. Topography Measurements. The mean increase of 𝐾max
was 2.88 ± 2.20D and 2.78 ± 1.87D in the T-ionto CL and
standard CL groups in the preceding 12 months, respectively.
At baseline, the difference in 𝐾max between groups was not
statistically significant (T-ionto CL: 54.7±4.0D; standard CL:
54.7 ± 4.3D; 𝑃 = 0.87). At 6 months, there was a significant
average improvement in both groupswith a flattening of𝐾max
by 0.72±1.20D(𝑃 = 0.01) and 0.86±0.89D(𝑃 = 0.006) in the
T-ionto CL and standard CL groups, respectively (Figure 3).
Flattening of more than 1.00D occurred in 7 eyes (32%) and 5
eyes (42%) in the T-ionto CL and control group, respectively.
Two eyes (9%; A1000 = 1.2D and A2200 = 1.2D) of the T-
ionto CL group showed progression of𝐾max more than 1.00D
during the same period; no eye showed progression in the
standard CL group. Comparing the 𝐾max changes between
groups revealed no statistically significant differences (𝑃 =
0.72) at 6 months (Figure 4).
3.5. Visual Acuity and Refractive Outcomes. At baseline, the
difference in BSCVA between groups was not statistically
significant (𝑃 = 0.29). On average, BSCVA improved
compared with baseline at 6 months in the T-ionto CL group
(from 0.12±0.20 logMAR to 0.01±0.10 logMAR; 𝑃 = 0.001).
In the control group, the 6-month improvement of BSCVA
compared with baseline approached statistical significance
(from 0.06 ± 0.10 logMAR to 0.01 ± 0.07 logMAR; 𝑃 = 0.08;
Figure 5(a)). At 6 months, BSCVA improved by 1 or more
ETDRS line in fourteen eyes (64%) and four eyes (33%) in
the T-ionto CL and control group, respectively. The changes
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(a)
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Figure 2: (a) Slit-lamp photographs of a representative case (A1200) after T-ionto CL. One day after treatment, moderate epithelial haze of
the central cornea (arrow), with no fluorescein staining, was noted in 5 cases (23%); this superficial haze regressed in all cases within 1 week
after treatment. Six months after T-ionto CL, the cornea was clear in all cases. (b) Slit-lamp photographs of a representative case (B700) after
standard CL. Six months after treatment, anterior corneal haze and mild stromal edema, which was confined to the posterior stroma, were
still observed in 50% and 8% of controls, respectively.
T-ionto CL
Standard CL
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Figure 3: Graph showing𝐾max readings (D) comparedwith baseline
at 3 days, 1 week, and 1, 3, and 6 months after T-ionto CL (black
curve) and standardCL (grey curve). Bars indicate± standard devia-
tion.On average, both procedures halted progression of keratoconus
during 6 months of follow-up.
of BSCVA between the two groups did not show statistical
significance (𝑃 = 0.19) at 6 months.
The contrast sensitivity function recovery was slower in
the control than in study group (𝑃 < 0.001 at day 3).
In the study group, CSF did not change during follow-up
(preoperative range: 1.20–1.65 log units; 6-month range: 1.35–
1.65 log units); in the control group, the postoperative values
decreased immediately after treatment (from 1.59 ± 0.12 to
1.36±0.22 log units at day 3,𝑃 < 0.001), approaching baseline
values at 1 week (1.54 ± 0.14 log units; Figure 5(b)). After 6
months, CSF improved by one triplet in seven eyes (32%)
and three eyes (25%) in the T-ionto CL and control group,
respectively.
The manifest spherical equivalent refraction changed
averagely by +0.65 ± 1.20D (𝑃 = 0.02) and +0.24 ± 0.77D
(𝑃 = 0.32) in the T-ionto CL and standard CL groups,
respectively, at 6 months. No significant difference in the
change ofmanifest refractionwas found between groups (𝑃 =
0.30) during 6 months of follow-up (Figure 5(c)).
3.6. Corneal Thickness Measurements. At baseline, the mean
central corneal thickness (CCT) was 484 ± 37 𝜇m and 494 ±
34 𝜇m in the T-ionto CL and standard CL group (𝑃 = 0.44),
respectively. At 6 months, no significant CCT differences
were found in the T-ionto CL (480 ± 33 𝜇m; 𝑃 = 0.50), while
significant corneal thinning was found in the control group
(481±29 𝜇m;𝑃 = 0.03) with respect to baseline (Figure 6(a)).
On average, corneal thickness significantly increased at 3 days
(𝑃 = 0.001) after standard CL, approaching baseline values at
1 week and slightly progressing to decrease over 6 months.
3.7. Endothelial Cell Density. The ECD ranged from 2635 ±
387 cells/mm2 and 2625 ± 281 cells/mm2 preoperatively to
2666 ± 235 cells/mm2 and 2647 ± 351 cells/mm2 6 months
postoperatively in the T-ionto CL (𝑃 = 0.66) and standard
CL (𝑃 = 0.68) group, respectively. In the control group, ECD
dropped at 3 days postoperatively (𝑃 = 0.03; Figure 6(b)),
likely related to the loss of corneal transparency due to
stromal edema found in 50% of eyes at the same visit.
3.8. Adverse Events. One eye in the standardCL group (B600;
left eye) showed two small peripheral subepithelial infiltrates
at day 3, which did not delay epithelial wounding and did
not affect visual acuity. The anterior chamber was clear. The
eye was treated with application of netilmicin sulfate 0.3%
(Nettacin, Sifi SpA, Italy) and ciprofloxacin chlorhydrate 0.3%
(Oftacilox, Alcon SA, Puurs, Belgium) drops 5 times daily
each for 7 days. Fluorometholone acetate 0.1% was initiated
1 week later than scheduled in the study protocol. By 3
months, there were only two faint corneal scars, with visual
performance being stable (BSCVA= 20/20 and CSF = 1.65 log
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Figure 4: Tangential corneal topography maps in a patient who underwent transepithelial corneal cross-linking in the right eye (A1500) and
standard cross-linking in the left eye (B700).The preoperative, 1-week, and 1-, 3-, and 6-month postoperative maps are shown from the left to
right, respectively. At 6 months, the flattening of 𝐾max was 1.74D (from 59.46D to 57.72D) and 0.92D (from 50.55D to 49.63D) in the right
and left eye, respectively. Scale bars are normalized and shown in diopters. RE: right eye; LE: left eye; 𝐾steep and 𝐾flat represent the simulated
keratometry values.
units). No postoperative complications occurred in the right
eye of the same subject (A1400) that underwent T-ionto CL.
4. Discussion
In this work, we reported the surgical techniques and
preliminary clinical findings of the RTC with code identi-
fier NCT02117999 comparing transepithelial corneal cross-
linking with iontophoresis and conventional corneal cross-
linking on all enrolled patients having completed 6 months
of follow-up.
The eyes recruited in both arms of the present study
showed similar progression of 𝐾max in the preceding 12
months, with mean steepening of 2.88 ± 2.20D and 2.78 ±
1.87D in the T-ionto CL and standard CL groups, respec-
tively. Because the main treatment objective is to stabilize
the underlying disease process, corneal topography (𝐾max)
at 12 months was considered the key outcome measure of
the study [1, 2]. Due to the inherent clinical interest in novel
surgical techniques for treating progressive keratoconus, we
are anticipating the 6-month clinical outcome.
At 6 months, we found statistically significant flattening
of 𝐾max by 0.72 ± 1.20D (𝑃 = 0.01) and 0.86 ± 0.89D
(𝑃 = 0.006) in the T-ionto CL and standard CL groups,
respectively, with no difference between groups, though
two eyes in the study group (9%) showed progression of
𝐾max of 1.2 D during the same period. Less variability and
more favorable outcomes have been in general reported for
standard cross-linking from the 6-month follow-up onwards,
due to epithelial-stromal remodelling [2, 3, 8, 12, 25, 26]; for
this reason, the design of the present RCT did not include
any further treatment before completing the 1-year follow-
up. Retreatment of an ectatic cornea has been previously
indicated if the 𝐾max value increased by at least 1.0D over 2
consecutive follow-up visits compared with its value during
the steady-state period after the first treatment [3].
Visual performance was not affected by T-ionto CL in
the first days after surgery; at 3 days postoperatively, all eyes
except for two (90%) had the same or improved BSCVA and
CSF with respect to baseline. The same result was found in
50% of cases treated by standard CL in the same period.
The differences between treatments were mostly related to
epithelial debridement and wound healing. Six months after
T-ionto CL, we found a significant average improvement in
BSCVA (−0.11 logMAR; 𝑃 = 0.001), which was not found
after standard CL. No change in CSF was found after T-
ionto CL (mean changes lower than +0.08 log units during
a period of 6 months), whereas a decrease in CSF was
measured 3 days after standard CL (on average, −0.23 log
units), which was likely caused by epithelial debridement and
wound healing.Themanifest refraction showed a statistically
significant average reduction of myopia (+0.65 ± 1.20D; 𝑃 =
0.02) only after T-ionto CL treatment at 6 months.
No changes in CCT and ECD were measured during
6 months of follow-up after T-ionto CL treatment. After
standard CL, corneal thickness increased, due to stromal
edema, during the first week postoperatively (on average,
+34 𝜇m), decreasing during 6-month follow-up. A drop in
ECD count, which was related to decreased transparency and
more corneal scattering caused by stromal swelling in 50% of
eyes, was measured at day 3 after standard CL (on average,
−337 cells/mm2). The use of hypotonic riboflavin solution
to promote stromal swelling in order to achieve a minimum
thickness of 400𝜇mbefore UV-A irradiation has been shown
to minimize the risk of early postoperative stromal swelling
[27].
Although there was no difference in pain score between
groups at any time during follow-up, symptoms of ocular
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Figure 5: ((a), (b), and (c)) Graphs showing best spectacle corrected visual acuity (BSCVA, LogMAR), contrast sensitivity function (CSF,
log units), and spherical equivalent refraction (D) compared with baseline at 3 days, 1 week, and 1, 3, and 6 months after T-ionto CL (black
curve) and standard CL (grey curve), respectively. Bars indicate ± standard deviation. BSCVA improved significantly (𝑃 = 0.08) and spherical
equivalent refraction was significantly less myopic (𝑃 = 0.02) after T-ionto CL. On average, visual performance decreased in the first week
after standard CL and reached preoperative values at 3 months postoperatively.
discomfort were greater after standard CL than after T-ionto
CL during the first 3 days postoperatively. The eyes treated
by standard CL showed greater conjunctival hyperaemia and
tarsal conjunctival papillae than eyes treated by T-ionto CL
during the first week [24]. At 3 months, 2 eyes (10%) in the
T-ionto CL group showed faint corneal haze (grade ≤ 0.5),
which disappeared in all cases at 6 months. In the control
group, six eyes (50%) showed mild corneal haze (grade
between 0.5 and 1.0) during the same period [23]. We had
one case in the control group that showed peripheral sterile
corneal infiltrates at day 3, which did not delay corneal wound
healing or affect visual performance or topography outcome
(𝐾max flattened by −0.8D at 6 months). No adverse events
were recorded in the study group.
Data from the control group are consistent with those
already published in the literature showing the time course
of clinical and instrumental measures after standard CL [2–5,
9, 25]. In general, visual acuity and corneal steepness worsen
in the first month postoperatively; resolution to baseline
occurs by approximately 3 months, with improvement there-
after. Improvement includes flattening of 𝐾max (on average
between 1 and 2D in averagely 50% of cases), reduction
in myopic spherical equivalent (averagely between +0.2 and
+0.7D), and increase of BSCVA (≥1 Snellen line in 50% of
cases), which occur during a period of 1 year after treatment
[2, 3, 8, 10, 25, 26]. Central corneal thickness remains slightly
decreased from baseline to 12 months after standard CL
and then recovers to baseline thickness after more than 18
months [8]. Early postoperative complications after standard
CL include stromal swelling (averagely 70% of cases) and
sterile infiltrates (averagely 8% of cases), which however have
been shown to resolve in the vast majority of cases within 3
months after treatment [2, 6, 28]. Stromal swelling may be
due to epithelial debridement, excessive stromal thinning due
to the hyperosmolar riboflavin solution, and the direct UV-A
irradiation of the corneal stroma.Themechanism underlying
sterile infiltration is still unknown butmay relate to an altered
immune response to antigens in areas of static tear pooling
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Figure 6: ((a) and (b)) Graphs showing central corneal thickness (CCT, 𝜇m) and endothelial cell density (ECD, cells/mm2) compared with
baseline at 3 days, 1 week, and 1, 3, and 6 months after T-ionto CL (black curve) and standard CL (grey curve), respectively. Bars indicate ±
standard deviation. No significant changes of CCT and ECD were found after T-ionto CL during 6 months of follow-up. Major differences
between treatments in the early postoperative period are due to consequences of epithelial debridement and direct UV-A irradiation of the
stroma thinned by hypertonic riboflavin solution.
beneath the bandage contact lens or may be a direct result
of the phototoxic effect of corneal cross-linking [28, 29].
Corneal haze is also a common adverse event in the early
postoperative period after standard CL (up to 70% of cases),
which however resolves in the vast majority of cases by 1 year
after treatment [28, 30, 31].
In this RCT, the major technical differences between the
T-ionto CL and standard CL treatments include the epithelial
debridement in the latter case, the use of two different
riboflavin solutions, and the totalUV-Aenergy dose delivered
to corneal stroma,which is on average 20%higher in standard
CL than in T-ionto CL, due to the UV-A filtering effect of the
epithelium [10].
Three previous uncontrolled studies [32–34] have
reported the clinical outcome of transepithelial corneal
cross-linking with iontophoresis for the management of
keratoconus in adults. In general, the authors have reported
an improvement in BSCVA, stable or decreased 𝐾max,
and no changes in CCT and ECD count during 1-year
follow-up. In two studies [33, 34], iontophoresis has been
performed with the same iontophoresis device used in
the present RCT. Recently, the 1-year clinical outcome of
transepithelial corneal cross-linking with iontophoresis (20
eyes) to treat progressive keratoconus has been compared
to the standard corneal cross-linking protocol (20 eyes).
The authors have shown a significant reduction of 𝐾max by
−0.31 ± 1.87D and −1.05 ± 1.51D, respectively, with no
patient eye showing continuous progression of keratoconus
at the end of follow-up [35].
In this trial, iontophoresis was preceded by removal of
precorneal mucin layer with the intent to increase epithelial
permeability to riboflavin (molecular weight of 340Da) [36–
39]. At physiologic pH, the intact corneal epithelial surface
acts as a chemophysical barrier due to the function of the
intercellular tight junctions and the epithelium-associated
mucins, which regulate paracellular transport of compounds
[22, 40]. By removing the epithelium-associated mucins,
we aimed to decrease the epithelial barrier function in
order to ensure enough bioavailability of riboflavin in the
stroma using iontophoresis, as found in laboratory studies
[21, 22]. Gentle applanation of the central corneal sur-
face with Biopore membrane for 3 seconds was effective
to remove the central precorneal tear film, as shown by
confocal immunofluorescence analysis of the membranes
containing MUC4 mucin, which is the predominant mucus
moiety in the precorneal tear film [38, 39], and by corneal
imaging using slit-lamp biomicroscopy and fluorescein dye
(molecular weight of 376Da). No damage to the corneal
epitheliumwasmade in any case and this clinical observation
was supported by the presence of only scattered superficial
epithelial cells on the Biopore membranes.
In conclusion, the preliminary outcome from the present
RCT provides evidence that transepithelial corneal cross-
linking with iontophoresis using 10mW/cm2 UV-A device
is safe for the treatment of progressive keratoconus in
adults and improves keratometry readings in 90% of cases
over 6 months postoperatively. Investigation of the long-
term RCT outcomes is warranted to verify the efficacy of
transepithelial corneal cross-linking and determine whether
it may be comparable with standard corneal cross-linking in
the management of progressive keratoconus.
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